Browse the full PubMed index: PubMed search
Think of diet as the soil medical treatment is still the seed
Loren Pickart first isolated it in 1973 while studying compounds involved in tissue repair and regeneration
GLP-1 therapies influence pathways tied to addiction and reward, according to the Endocrine Society A randomized clinical trial published in JAMA Psychiatry found semaglutide reduced alcohol cravings and consumption Users commonly report: Reduced desire to drink Feeling full faster when drinking Less reward from alcohol The data: early, but directionally consistent While long-term industry sales data is still developing, the early signals from clinical studies, observational research, and population polling all point in the same direction: GLP-1 use is associated with lower alcohol consumption for at least some users
[24] [25] It's important to note that while both medications can affect lipid parameters, large clinical trials (AIM-HIGH and HPS2-THRIVE) have not demonstrated cardiovascular outcome benefits from adding niacin to statin therapy
This post will explore the current scientific research regarding the link between GLP-1 medications and kidney health